ALBATROSS with GLPG2222 shows positive clinical results in CF patients
Evaluation of C1 corrector GLPG2222 on top of ivacaftor (Kalydeco®[1]) in heterozygous Class III/F508del CFTR patients Patient study recruited within 5 months in Europe and Australia GLPG2222 was well tolerated dosed once daily for 28 days Dose dependent …